OrthoPediatrics Corp., a medical device company, engages in designing, developing, and marketing anatomically appropriate implants, instruments, and specialized braces for children with orthopedic conditions in the United States and internationally. The company offers pediatric trauma and deformity correction products; scoliosis procedures for the treatment of spinal deformity in children; and sports medicine and other products. Its products comprise PediLoc, PediPlates, cannulated screws, PediFlex nail, PediNail, PediLoc Tibia, ACL Reconstruction System, Locking Cannulated Blade, Locking Proximal Femur, Spica Tables, RESPONSE Spine, BandLoc, Pediatric Nailing Platform | Femur, Devise Rail, Orthex, The Fassier-Duval Telescopic Intramedullary System, SLIM Nail, The GAP Nail, The Free Gliding SCFE Screw System, GIRO Growth Modulation System, PNP Tibia System, ApiFix Mid-C System, Mitchell Ponseti, and Boston Brace 3D. The company serves pediatric orthopedic market, as well as pediatric orthopedic surgeons and caregivers. OrthoPediatrics Corp. was founded in 2006 and is headquartered in Warsaw, Indiana.
Pediatric Orthopedics | OrthoPediatrics Corp. dominates the niche pediatric orthopedic market, leveraging specialized focus to drive impressive growth and expand market presence |
Financial Momentum | Explore OrthoPediatrics' robust financial performance, with Q3 2024 revenue surpassing estimates and full-year guidance raised to $202-$204 million |
Strategic Expansion | Delve into the company's ambitious clinic network expansion plans, aiming to open 18 new markets by 2027 and strengthen its market position |
Future Projections | Analysts project revenue to reach $242-$244 million by 2025, with improving profitability and a target price of $50 set by JMP Securities |
Metrics to compare | KIDS | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipKIDSPeersSector | |
---|---|---|---|---|
P/E Ratio | −12.0x | −3.4x | −0.5x | |
PEG Ratio | 0.17 | −0.20 | 0.00 | |
Price/Book | 1.4x | 3.1x | 2.6x | |
Price / LTM Sales | 2.3x | 3.3x | 3.3x | |
Upside (Analyst Target) | 106.7% | 42.5% | 42.8% | |
Fair Value Upside | Unlock | 4.2% | 6.5% | Unlock |